ATE203162T1 - Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one - Google Patents

Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one

Info

Publication number
ATE203162T1
ATE203162T1 AT94901556T AT94901556T ATE203162T1 AT E203162 T1 ATE203162 T1 AT E203162T1 AT 94901556 T AT94901556 T AT 94901556T AT 94901556 T AT94901556 T AT 94901556T AT E203162 T1 ATE203162 T1 AT E203162T1
Authority
AT
Austria
Prior art keywords
alpha
androst
aza
beta
pct
Prior art date
Application number
AT94901556T
Other languages
English (en)
Inventor
Glenn J Gormley
Elizabeth Stoner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE203162T1 publication Critical patent/ATE203162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT94901556T 1992-12-18 1993-11-18 Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one ATE203162T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99298592A 1992-12-18 1992-12-18
PCT/US1993/011155 WO1994014452A1 (en) 1992-12-18 1993-11-18 METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES

Publications (1)

Publication Number Publication Date
ATE203162T1 true ATE203162T1 (de) 2001-08-15

Family

ID=25538974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94901556T ATE203162T1 (de) 1992-12-18 1993-11-18 Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one

Country Status (17)

Country Link
US (1) US5629318A (de)
EP (1) EP0674521B1 (de)
JP (1) JPH08504813A (de)
AT (1) ATE203162T1 (de)
AU (1) AU691164B2 (de)
CA (1) CA2151239A1 (de)
CZ (1) CZ285379B6 (de)
DE (1) DE69330465T2 (de)
DK (1) DK0674521T3 (de)
ES (1) ES2158887T3 (de)
FI (1) FI953002L (de)
GR (1) GR3036241T3 (de)
HU (1) HU220064B (de)
NO (1) NO308829B1 (de)
NZ (1) NZ258435A (de)
PT (1) PT674521E (de)
WO (1) WO1994014452A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3993899A (en) * 1998-05-18 1999-12-06 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
US7446110B2 (en) * 2003-09-10 2008-11-04 Merck & Co., Inc. 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
JP2007509962A (ja) * 2003-10-31 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としての２１−複素環−４−アザステロイド誘導体
US20080268463A1 (en) * 2007-03-07 2008-10-30 Children's Medical Center Corporation Methods for Prognosis and Diagnosis of Chronic Prostatitis/Pelvic Pain Syndrome and Interstitial Cystitis
RU2525182C1 (ru) * 2013-02-28 2014-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения больных хроническим простатитом с парциальным андрогенодефицитом
CN104161739B (zh) * 2014-08-15 2017-09-19 武汉人福药业有限责任公司 非那雄胺胶囊及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2227876A (en) * 1937-10-16 1941-01-07 Firm Of N V Organon Steroid derivatives with nuclear substituted nitrogen
US3285918A (en) * 1962-04-18 1966-11-15 Norman J Doorenbos 1', 4', 5', 6'-tetrahydropyrimidino[a-4, 3]-4-aza-5-cholestene
US3239417A (en) * 1962-12-07 1966-03-08 Smith Kline French Lab Methods and compositions for inhibiting sterol biosynthesis
US3264301A (en) * 1963-08-22 1966-08-02 Norman J Doorenbos Substituted-4-azasteroids
FR1465544A (fr) * 1965-11-29 1967-01-13 Roussel Uclaf Dérivés stéroïdes aromatiques substitués par un atome d'azote endocyclique et procédé de préparation
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0285383B1 (de) * 1987-04-03 1994-03-16 Merck & Co. Inc. Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen
US4946688A (en) * 1988-07-05 1990-08-07 Fahim Mostafa S Intraprostatic injection of zinc ions for treatment of inflammatory conditions and benign and malignant tumors of the prostate
DK627289D0 (da) * 1989-12-12 1989-12-12 Per C Oden Anvendelse af bicyclononanderivater
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
EP0663924B1 (de) * 1992-10-06 2001-02-14 Merck & Co. Inc. 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel

Also Published As

Publication number Publication date
EP0674521B1 (de) 2001-07-18
ES2158887T3 (es) 2001-09-16
WO1994014452A1 (en) 1994-07-07
GR3036241T3 (en) 2001-10-31
FI953002A7 (fi) 1995-06-16
CA2151239A1 (en) 1994-07-07
NO952427D0 (no) 1995-06-16
EP0674521A4 (de) 1998-02-04
FI953002A0 (fi) 1995-06-16
DK0674521T3 (da) 2001-09-24
AU5610594A (en) 1994-07-19
PT674521E (pt) 2001-10-31
JPH08504813A (ja) 1996-05-28
FI953002L (fi) 1995-06-16
DE69330465T2 (de) 2002-04-25
US5629318A (en) 1997-05-13
CZ285379B6 (cs) 1999-07-14
DE69330465D1 (de) 2001-08-23
HUT73231A (en) 1996-07-29
NO952427L (no) 1995-06-16
NO308829B1 (no) 2000-11-06
NZ258435A (en) 1997-05-26
AU691164B2 (en) 1998-05-14
CZ157795A3 (en) 1995-11-15
HU220064B (hu) 2001-10-28
HU9501777D0 (en) 1995-08-28
EP0674521A1 (de) 1995-10-04

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69727695D1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
EP1005349A4 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
DE69232629D1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE344668T1 (de) Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE59102745D1 (de) Verfahren une einrichtung zur behandlung von saatgut.
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE200805T1 (de) Verfahren zur reduktion von schwefel- und küpenfarbstoffen
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
BR9906803A (pt) Processo para tratamento de copd
DE59305800D1 (de) Werkzeug zur behandlung von oberflächen von bauteilen
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee